Connie Batlevi, MD

home / authors / connie-batlevi-md

Articles

Dr. Batlevi on the Role of Active Surveillance in Advanced-Stage Follicular Lymphoma

Dr. Batlevi on the Role of Active Surveillance in Advanced-Stage Follicular Lymphoma

Connie Batlevi, MD
September 28th 2020

Connie L. Batlevi, MD, PhD, discusses the role of active surveillance in advanced​-stage follicular lymphoma. 

Read More

Dr. Batlevi on Emerging Therapies in Follicular Lymphoma

Dr. Batlevi on Emerging Therapies in Follicular Lymphoma

Connie Batlevi, MD
September 25th 2020

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Read More

Dr. Batlevi on Challenges Faced in Follicular Lymphoma Management

Dr. Batlevi on Challenges Faced in Follicular Lymphoma Management

Connie Batlevi, MD
September 18th 2020

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Read More

Dr. Batlevi on Safety With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

Dr. Batlevi on Safety With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

Connie Batlevi, MD
June 14th 2017

Connie Batlevi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety results of a phase I study evaluating the combination of ibrutinib (Imbruvica) and buparlisib in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need